MAPT and Alzheimer disease: Collectively, these findings highlight AQ as a promising multi-target therapeutic candidate that simultaneously regulates Aβ and tau aggregation, attenuates their associated inflammatory responses, and reduces Aβ pathology, thereby supporting its potential as a therapeutic candidate for AD.